Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Short-term Investments (2016 - 2025)

Historic Short-term Investments for ImmunityBio (IBRX) over the last 11 years, with Q3 2025 value amounting to $197.6 million.

  • ImmunityBio's Short-term Investments rose 97370.25% to $197.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $197.6 million, marking a year-over-year increase of 97370.25%. This contributed to the annual value of $6.4 million for FY2024, which is 53240.83% up from last year.
  • As of Q3 2025, ImmunityBio's Short-term Investments stood at $197.6 million, which was up 97370.25% from $16.0 million recorded in Q2 2025.
  • Over the past 5 years, ImmunityBio's Short-term Investments peaked at $197.6 million during Q3 2025, and registered a low of $931000.0 during Q1 2025.
  • In the last 5 years, ImmunityBio's Short-term Investments had a median value of $16.0 million in 2025 and averaged $41.0 million.
  • As far as peak fluctuations go, ImmunityBio's Short-term Investments crashed by 9821.29% in 2023, and later soared by 348966.5% in 2024.
  • Over the past 5 years, ImmunityBio's Short-term Investments (Quarter) stood at $136.0 million in 2021, then crashed by 98.13% to $2.5 million in 2022, then plummeted by 60.32% to $1.0 million in 2023, then surged by 532.41% to $6.4 million in 2024, then surged by 2996.25% to $197.6 million in 2025.
  • Its last three reported values are $197.6 million in Q3 2025, $16.0 million for Q2 2025, and $931000.0 during Q1 2025.